Jonathan R. Anolik, MD, FACP, FACE, Professor of Clinical Medicine at the Lewis Katz School of Medicine at Temple University, has commented to HealthCentral regarding a recent study published in the New England Journal of Medicine. The study explores the use of manufactured stem cells as a potential cure for Type 1 Diabetes (T1D).
Dr. Anolik’s perspective was sought in light of findings that suggest progress toward treating T1D with new cell-based therapies. He provided insight into what these results could mean for future treatment options.
Temple University Hospital has also announced that starting September 3 at 8:00 AM, Labor and Delivery services will be discontinued at its Main Campus on Broad and Ontario Streets. All childbirth services will move to a new hospital location.
